Javascript must be enabled to continue!
Use of the corneal bioreactor to assess deswelling efficacy of hyperosmotic eye drops
View through CrossRef
AbstractPurposeThe preclinical testing of the efficacy and safety of hyperosmotic anti‐edematous eye drops is complicated by the lack of a simple in vivo and ex vivo animal model. Our patented corneal bioreactor (BR) allows prolonged preservation of the human cornea by restoring physiological intraocular pressure and renewing the culture medium. Under certain experimental conditions, the corneas preserved in BR are nevertheless thicker than normal (684 ± 52 um, A J Transplantation 2019).AimTo use this characteristic of corneas stored in the BR to test the efficacy of new hyperosmotic eye drops prototypes.MethodsHuman corneas (n = 4) discarded by our eye banks were used whatever their endothelial status. They were first stored for 2 weeks into the BR filled with CorneaMax (Eurobio, France), with 21 mmHg in the endothelial chamber to allow regeneration of a normal epithelium as previously shown. Using a specific BR lid allowing sterile instillation in front of corneal center, each cornea was treated topically with 3 drops, every 2 hr, repeated 3 times. The epithelial chamber was emptied just before instillation and filled again with CorneaMax 2 min after instillation. Three corneas were treated with a commercial eyedrop containing 5% NaCl and 0.15% sodium hyaluronate and one cornea with Balanced Salt Solution (BSS) as a control. Central corneal volume (on an 8mm disc, CCV8 in mm3) was measured with OCT (Casia, Tomey) immediately before and after each instillation. The decrease in CCV was calculated for each instillation and before the first and the third instillation.ResultsFor corneas treated with NACl 5%, CCV decreased by (mean ± SD) 1.0 ± 0.4, 0.7 ± 0.1 and 0.6 ± 0.2 mm3, respectively, for the first, the second and the third instillation, and globally by 2.4 ± 1.1 mm3. The cornea treated with BSS remained unchanged.ConclusionsThe BR is an efficient tool to quantify the efficacy of hyperosmotic eye drops designed to deswell human cornea.
Title: Use of the corneal bioreactor to assess deswelling efficacy of hyperosmotic eye drops
Description:
AbstractPurposeThe preclinical testing of the efficacy and safety of hyperosmotic anti‐edematous eye drops is complicated by the lack of a simple in vivo and ex vivo animal model.
Our patented corneal bioreactor (BR) allows prolonged preservation of the human cornea by restoring physiological intraocular pressure and renewing the culture medium.
Under certain experimental conditions, the corneas preserved in BR are nevertheless thicker than normal (684 ± 52 um, A J Transplantation 2019).
AimTo use this characteristic of corneas stored in the BR to test the efficacy of new hyperosmotic eye drops prototypes.
MethodsHuman corneas (n = 4) discarded by our eye banks were used whatever their endothelial status.
They were first stored for 2 weeks into the BR filled with CorneaMax (Eurobio, France), with 21 mmHg in the endothelial chamber to allow regeneration of a normal epithelium as previously shown.
Using a specific BR lid allowing sterile instillation in front of corneal center, each cornea was treated topically with 3 drops, every 2 hr, repeated 3 times.
The epithelial chamber was emptied just before instillation and filled again with CorneaMax 2 min after instillation.
Three corneas were treated with a commercial eyedrop containing 5% NaCl and 0.
15% sodium hyaluronate and one cornea with Balanced Salt Solution (BSS) as a control.
Central corneal volume (on an 8mm disc, CCV8 in mm3) was measured with OCT (Casia, Tomey) immediately before and after each instillation.
The decrease in CCV was calculated for each instillation and before the first and the third instillation.
ResultsFor corneas treated with NACl 5%, CCV decreased by (mean ± SD) 1.
0 ± 0.
4, 0.
7 ± 0.
1 and 0.
6 ± 0.
2 mm3, respectively, for the first, the second and the third instillation, and globally by 2.
4 ± 1.
1 mm3.
The cornea treated with BSS remained unchanged.
ConclusionsThe BR is an efficient tool to quantify the efficacy of hyperosmotic eye drops designed to deswell human cornea.
Related Results
Poloxamines for Deswelling of Organ-Cultured Corneas
Poloxamines for Deswelling of Organ-Cultured Corneas
<b><i>Background:</i></b> Poloxamines are amphiphilic tetrofunctional block copolymers composed of four polyoxyethylene-polyoxypropylene arms joined to a ce...
A retrospective analysis of outcomes of an optical reconstructive surgery combined with corneal transplantation dedicated to manage complications of inflammatory diseases of the anterior chamber of the ey
A retrospective analysis of outcomes of an optical reconstructive surgery combined with corneal transplantation dedicated to manage complications of inflammatory diseases of the anterior chamber of the ey
Background: full thickness corneal transplantation or penetrating keratoplasty (PK) is the only surgical method to manage outcomes of
inflammatory diseases of the anterior eye cham...
Surface modification treatments to enhance the performance of titanium backplate in keratoprosthesis
Surface modification treatments to enhance the performance of titanium backplate in keratoprosthesis
(English) The cornea is the outermost layer of the eye, essential for vision as it provides protection and contributes 80% of the eye’s refractive power. Its transparency and lack ...
Corneal Ulcer in a Sheep - Treatment with Third Eyelid Flap
Corneal Ulcer in a Sheep - Treatment with Third Eyelid Flap
Background: Corneal ulcers are frequently reported in the literature in several species, however, the treatment of traumatic lesions on the corneal surface of ruminants is still po...
Overexpression of TRPV1 activates autophagy in human lens epithelial cells under hyperosmotic stress through Ca2+-dependent AMPK/mTOR pathway
Overexpression of TRPV1 activates autophagy in human lens epithelial cells under hyperosmotic stress through Ca2+-dependent AMPK/mTOR pathway
AIM: To explore whether autophagy functions as a cellular adaptation mechanism in lens epithelial cells (LECs) under hyperosmotic stress.
METHODS: LECs were treated with hyperosmot...
Novel Treatment Options for Corneal Edema
Novel Treatment Options for Corneal Edema
Introduction: The current treatment of corneal edema is limited to hyperosmotic saline mixtures. Usually the therapy consists of treatment with hypertonic 5% NaCl eye drops or 6% e...
Effects of TGFB1 and 17 B estradiol on corneal stiffness and thickness
Effects of TGFB1 and 17 B estradiol on corneal stiffness and thickness
Background: Impaired corneal stiffness and transparency are the hallmarks of some of the leading global causes of corneal blindness diseases, such as keratoconus (KCN) which is cha...
Evaluation of preoperative dry eye in people undergoing corneal refractive surgery to correct myopia
Evaluation of preoperative dry eye in people undergoing corneal refractive surgery to correct myopia
AIM: To investigate the incidence of preoperative dry eye and related factors in patients undergoing corneal refractive surgery to correct myopia.
METHODS: A total of 141 patients ...

